Literature DB >> 19843839

Safety of concomitant tamoxifen and warfarin.

Carrie B Givens1, Laura N Bullock, Andrea S Franks.   

Abstract

OBJECTIVE: To review the literature regarding the potential interaction between tamoxifen and warfarin. DATA SOURCES: A search of MEDLINE from 1948 to August 20, 2009, was performed using the search terms tamoxifen, warfarin, drug interactions, and cytochrome P450 2C9. EMBASE was searched (1980-week 33, 2009), using the search terms tamoxifen and warfarin, for articles limited to use in humans and published in English, then further narrowed to drug interactions. Bibliographic review was conducted but did not reveal any additional references. STUDY SELECTION AND DATA EXTRACTION: All sources evaluated were published in English and included original case reports, letters, and medical record or database reviews that described an interaction between warfarin and tamoxifen. DATA SYNTHESIS: Since tamoxifen therapy and cancer increase the risk of venous thromboembolism, warfarin may be prescribed to these patients. However, product information, primary literature, and tertiary literature describe concomitant use of tamoxifen and warfarin as a contraindication since this may increase the level of anticoagulation and the risk of bleeding complications. Although the exact mechanism of the interaction is unknown, one theory is that tamoxifen inhibits CYP2C9, which metabolizes the S-isomer of warfarin. Five publications were identified including 2 letters, 2 individual case reports, and 2 retrospective reviews (1 of the case reports was included in a medical record review). Collectively, these articles described a total of 31 patients taking warfarin and tamoxifen concomitantly, with 8 patients experiencing bleeding complications.
CONCLUSIONS: Although concomitant use of warfarin and tamoxifen is deemed a contraindication, evidence regarding this potential interaction is limited. Therefore, safety of concomitant use of tamoxifen and warfarin may be similar to that of other drugs that interact with warfarin, requiring consistent and careful monitoring. However, more evidence is needed to warrant the routine use of this combination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843839     DOI: 10.1345/aph.1M176

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  4 in total

1.  Tamoxifen Pharmacovigilance: Implications for Safe Use in the Future.

Authors:  Demetra Antimisiaris; Ki-Hwan Gabriel Bae; Laura Morton; Zahara Gully
Journal:  Consult Pharm       Date:  2017-09-01

2.  Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.

Authors:  Miia Turpeinen; Jouko Uusitalo; Terhi Lehtinen; Marita Kailajärvi; Olavi Pelkonen; Jouni Vuorinen; Pasi Tapanainen; Camilla Stjernschantz; Risto Lammintausta; Mika Scheinin
Journal:  Int J Mol Sci       Date:  2013-07-05       Impact factor: 5.923

3.  A pilot study on the impact of known drug-drug interactions in cancer patients.

Authors:  Silvia Ussai; Riccardo Petelin; Antonio Giordano; Mario Malinconico; Donatella Cirillo; Francesca Pentimalli
Journal:  J Exp Clin Cancer Res       Date:  2015-08-25

4.  Hypercoagulation from Concomitant Administration of Tamoxifen and Warfarin.

Authors:  Ladan Panahi; Javier A Saenz Ii; Nam Nguyen; George Udeani; Salim Surani
Journal:  Cureus       Date:  2020-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.